HK Stock Market Move | InnoCare Pharma (09969) rose nearly 3% as Mesutoclax's research on treating myeloid malignancies was selected for an oral presentation at the 2026 ASCO Annual Meeting.
China Resources Pharmaceutical Group (09969) rose nearly 3%, as of the time of this report, it had risen by 2.67%, reaching 14.24 Hong Kong dollars, with a trading volume of 29.1993 million Hong Kong dollars.
InnoCare Pharma (09969) rose nearly 3%, at the time of writing, it rose by 2.67% to HK$14.24, with a turnover of HK$29.1993 million.
On the news front, on April 27th, according to InnoCare Pharma's official WeChat account, the company announced that the research results of its self-developed new BCL2 inhibitor Mesutoclax (ICP-248) and the new BTK inhibitor Obutinib have been selected for presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Among them, the research on Mesutoclax for the treatment of myeloid malignancies was selected for oral presentation, and the research on Mesutoclax for the treatment of B-cell malignancies was selected for poster presentation.
Related Articles
Radical investor Starboard is aggressively acquiring shares in Dynatrace (DT.US): moving into the top five shareholders and pushing for a $2.5 billion buyback of shares within three years.
Joby Aviation (JOBY.US) completes first flight from New York's Kennedy Airport to Manhattan, accelerating the commercialization process of eVTOL.
HK Stock Market Move | CONANT OPTICAL (02276) fell over 4% in early trading, with Macquarie downgrading its earnings per share forecast to reflect a decrease in AI glasses revenue forecast and share capital adjustment.
Radical investor Starboard is aggressively acquiring shares in Dynatrace (DT.US): moving into the top five shareholders and pushing for a $2.5 billion buyback of shares within three years.
Joby Aviation (JOBY.US) completes first flight from New York's Kennedy Airport to Manhattan, accelerating the commercialization process of eVTOL.
HK Stock Market Move | CONANT OPTICAL (02276) fell over 4% in early trading, with Macquarie downgrading its earnings per share forecast to reflect a decrease in AI glasses revenue forecast and share capital adjustment.
